15 Best S&P 500 Dividend Stocks to Buy Now

6. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 85

AbbVie Inc. (NYSE:ABBV) is an American multinational biopharmaceutical company. The stock has surged by over 15% in the past 12 months, grabbing investors’ attention. The company is a major player in the pharmaceutical industry, offering a diverse range of treatments across immunology, oncology, neuroscience, and eye care. In addition to its medical therapies, it markets well-known aesthetic treatments such as Botox and Juvederm, widely used for anti-aging skincare. Its strong focus on innovation, along with its extensive product portfolio, solidifies its status as a blue-chip stock and an attractive investment option.

AbbVie Inc. (NYSE:ABBV) is a solid dividend payer, having raised its payouts for 52 consecutive years, which makes it one of the best dividend stocks on our list. The company’s quarterly dividend comes in at $1.64 per share and has a dividend yield of 3.19%, as of February 27.

AbbVie Inc. (NYSE:ABBV) posted fourth-quarter revenue of $15.1 billion, marking a 5.6% increase from the previous year and surpassing analysts’ projections of $14.87 billion. On a GAAP basis, it reported a net loss of $0.02 per share for the quarter. However, adjusted diluted earnings per share (EPS) came in at $2.16, slightly above the anticipated $2.13. For 2024, combined sales of Skyrizi and Rinvoq totaled $17.7 billion, reflecting a 51% annual increase, fueled by rising global demand and ongoing market expansion. Excluding Humira, the company’s total revenue grew 18% year-over-year, supported by strong performance in its neuroscience and oncology segments.